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Abstract Multiple independent genomic profiling efforts
have recently identified clinically and molecularly distinct
subgroups of ependymoma arising from all three anatomic
compartments of the central nervous system (supratentorial brain, posterior fossa, and spinal cord). These advances
motivated a consensus meeting to discuss: (1) the utility
of current histologic grading criteria, (2) the integration
of molecular-based stratification schemes in future clinical trials for patients with ependymoma and (3) current

therapy in the context of molecular subgroups. Discussion
at the meeting generated a series of consensus statements
and recommendations from the attendees, which comment
on the prognostic evaluation and treatment decisions of
patients with intracranial ependymoma (WHO Grade II/III)
based on the knowledge of its molecular subgroups. The
major consensus among attendees was reached that treatment decisions for ependymoma (outside of clinical trials)
should not be based on grading (II vs III). Supratentorial
and posterior fossa ependymomas are distinct diseases,
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although the impact on therapy is still evolving. Molecular
subgrouping should be part of all clinical trials henceforth.

The utility of histologic grading of ependymoma
in a molecular era

Keywords Ependymoma · Subgroups · RELA · YAP1 ·
Treatment · Trial · Posterior fossa

Ependymoma is a histologically defined intrinsic tumor that
involves the three major anatomic compartments (supratentorial brain, posterior fossa, and spinal cord) of the central
nervous system and affects both children and adults. The
current standard of care therapy for patients with intracranial ependymoma remains surgical resection combined
with radiotherapy. The survival benefit of chemotherapy
for ependymoma and the prognostic ability of histopathological grading criteria to risk-stratify patients are still both
inconclusive and contentious. No molecular or tumor-specific immunohistochemical markers are in routine current
clinical use for ependymoma. Recent advances in the biological characterization of ependymal tumors have demonstrated the existence of nine clinically, demographically, and
molecularly distinct entities, with three occurring in each
anatomic compartment. These findings offer new opportunities to create a precise, reliable, and objective platform for
stratification of ependymoma patients, and the potential for
altering therapeutic decisions based on molecular features.
Herein, we discuss the current consensus on the molecular
subgroups of intracranial ependymoma (WHO Grade II/
III) in children and adults, as well as recommendations for
integration into future clinical trial designs. These discussions and recommendations were made by a collection of
neuro-oncologists, neurosurgeons, neuro-pathologists, radiation oncologists, and basic scientists, meeting at the global
ependymoma consensus conference (Huntsville, Ontario,
Canada in September 2015) (Fig. 1).

Ependymomas from throughout the central nervous system
are currently sub-divided by three histology-based grades
used to predict the natural course of the disease and patient
outcome [19]. However, the utility of histological grading
of ependymoma for risk stratification has been controversial and without consistent associations of tumor grade with
patient outcome. The World Health Organization (WHO)
Grade I tumors include myxopapillary ependymoma, which
typically occurs in the spine, as well as subependymoma,
which is usually intracranial. Grade I ependymomas are
relatively easier to distinguish, occur predominantly in
adults, and are associated with favorable clinical outcomes
[19]. Conventional ependymomas are divided between
WHO Grade II and WHO Grade III (anaplastic) tumors, the
latter showing elevated mitotic activity, microvascular proliferation, and tumor necrosis. Analysis of multiple cohorts
of intracranial ependymoma highlights a wide variance in
the utility of the Grade II versus Grade III distinction as
a robust prognostic marker [9]. Furthermore, the utility of
conventional histologic grading may be confounded by
the anatomic compartment [29, 37]. These considerations
have raised significant questions as to whether the grading
criteria should stratify patients into different therapeutic
regimens. It was therefore agreed upon that: (1) treatment
decisions for ependymoma should not be based on classification and grading that is solely based on histopathological characteristics (especially, the distinction of Grade
II versus Grade III tumors) and (2) central and combined
histologic–molecular review and classification should be
a principal and integral component of any future clinical
trial. Indeed, the updated 4th edition of the WHO classification of central nervous system tumors recognizes the
supratentorial molecular variant, ST-EPN-RELA (see next
section), as a distinct biological and clinical disease entity
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Fig. 1  General and molecular subgroup specific consensus statements on the clinical management of intracranial ependymoma

[20]. Integrated histo-molecular analyses of ependymal
tumors from clinically well-annotated prospective international trial cohorts hold promise for inclusion of additional
molecular ependymoma ‘entities’ into the upcoming 5th
edition of the WHO classification of CNS tumors.

Molecular subgroups of ependymal tumors in the
central nervous system
Although molecular subgroups of ependymoma arising in
different anatomical sites exhibit histopathological similarities, their molecular profiles are easily discernable, owing
to diverse genetic, transcriptional, and epigenetic programs
[7, 8, 18, 22, 24, 30, 36, 37]. Functional cross-species
analyses have provided evidence that these molecular differences may be reflective of discrete developmental and
cellular origins [16, 30, 33]. Based on demographic, clinical, and molecular data, supported in multiple independent
cohorts [23, 29–31, 36, 37], a full consensus was reached
that: posterior fossa and supratentorial ependymoma are
biologically different diseases both treated by surgery and
radiotherapy. Future molecular characterization and clinical

trials will assess whether posterior fossa and supratentorial
ependymoma may benefit from different forms of therapy.
A recent international collaborative study identified nine
molecular subgroups of ependymal tumors, three in each
anatomical compartment of the central nervous system,
spine (SP), posterior fossa (PF), and supratentorial region
(ST) [29]. One of the subgroups within each compartment
was enriched with WHO Grade I subependymomas (SE),
named ST-SE, PF-SE, and SP-SE. These molecular subependymomas occurred in adults only. The two other molecular subgroups within the spine predominantly matched the
histopathology-based diagnoses of myxopapillary ependymoma (SP-MPE) and (WHO Grade II/III) ependymoma
(SP-EPN). The remaining two molecular types of ependymoma occurred in the posterior fossa, termed PF-EPNA and PF-EPN-B or alternatively posterior fossa Group A
and B, and were independently identified in retrospective
studies [36, 37]. PF-EPN-A tumors occur predominantly in
infants and young children. Due to their predominant lateral localization, PF-EPN-A tumors are often difficult to
completely resect and are associated with high recurrence
rates [37]. Conversely, PF-EPN-B tumors occur largely
in adolescents and young adults and are associated with a
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more favorable prognosis. More than 70% of supratentorial ependymomas are characterized by fusions between
C11ORF95 and the RELA gene, and were recently termed
ST-EPN-RELA [29, 30]. While ST-EPN-RELA tumors
may occur in both children and adults, the remaining
molecular subgroup of supratentorial ependymoma harbors
recurrent fusions to the oncogene YAP1 and is enriched
in the pediatric population [29, 30]. Since preliminary
evidence of a small retrospective cohort indicates that
patients with YAP1 fusions have an excellent prognosis, it
was agreed upon that the international community should
move rapidly toward determining whether ST-EPN-YAP1
is a subgroup with an extremely favorable clinical outcome
and therefore might benefit from careful therapy de-escalation within the setting of a clinical trial. Retrospective
classification of clinically well-annotated supratentorial
ependymomas, which have been treated in clinical trials,
is expected to give more detailed information on outcome
within this subgroup in the near future. No consensus was
made upon morphologically diagnosed ST-ependymomas
without RELA/YAP1 fusion. It was felt that further investigation was needed for this apparently heterogeneous group
of tumors. It was acknowledged that such issues could be
addressed with a DNA methylation-based molecular classification for ependymal tumors that represents an unbiased,
robust, and uniform scheme that adequately reflects the full
biological, clinical, and histopathological heterogeneity
across all age groups, grades, and major anatomical CNS
compartments. The clinical feasibility of this platform is
supported by multiple components: (1) low sample input
and DNA requirements, (2) robust results from formalinfixed paraffin-embedded (FFPE) tissue, and (3) minimal
batch effects and assay consistency between different clinical-genomic facilities. In addition to DNA methylation patterns, DNA copy number profiles can be derived from this
analysis. It is important to note that chromosome 1q gain
has been shown to be an independent prognostic factor that
occurs in a subset of PF-EPN-A, PF-EPN-B, and ST-EPNRELA tumors [12, 17, 24, 29, 32, 37]. Future integrated
molecular efforts will explore the integration of molecular
subgroup, copy number alterations (namely chromosome
1q gain), and their impact on patient outcome.
Molecular sub-classification is expected to significantly
support treatment decisions and simplify risk stratification
processes in the immediate future, and should impact clinical trial design and operation in both children and adults. A
complete consensus was reached that molecular subgrouping should be a part of all clinical trials moving forward. It
was agreed that certification of diagnostic assays for molecular subgroup detection is of high importance. However,
it was acknowledged that there were differences between
countries regarding certifying agencies and regulations,
and therefore most attendees felt that it was not reasonable
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and feasible to generate a consensus statement on certification processes. To further improve molecular diagnostics and identify new prognostic factors and therapeutic
targets, optimal tissue material for ongoing and future
biologic discovery studies is required. The great majority
of attendees agreed that submitting fresh-frozen samples
should be mandatory within upcoming clinical trials for
ependymoma. Although DNA methylation profiling can be
performed with FFPE-derived tissue, frozen samples would
provide optimal material for use in future applications,
such as genome sequencing. The interpretation of any
tumor sequencing (from a limited gene panel up to whole
genome) would dramatically benefit from a matched control to correct for aberrations inherent to the germline. As
such, an agreement among most attendees was established
that submission of blood samples should also be mandatory
for enrollment in a clinical trial. It should be recognized
that arguments were made against the mandate of freshfrozen tissue, owing to the logistical issues of collection,
storage, and submission, particularly in small community
centers. Additionally, there were ethical concerns regarding
the mandated submission of blood. Attendees recognized
that efforts would need to be established to create standard
operating procedures in smaller centers to enable reliable
collection and submission of frozen tissue. Many of those
agreeing on a mandate of frozen tissue and blood argued
that given the rapid developments in the field of molecular
genetics, with the emergence of increasingly powerful analytical devices and computational tools, the time is now to
collect tissue specimens in combination with high-quality
clinical data. This would enable the use of such advances to
improve the care of future ependymoma patients.

Clinical management of intracranial ependymoma
in the context of molecular subgroups
Clinical management of intracranial ependymomas (WHO
Grade II/III) is challenging and the optimal treatment strategy is contentious. Intracranial ependymoma, particularly
before administration of any therapy, demonstrates predominantly locally invasive growth patterns and has only
very low metastatic potential. Surgery plays a primary
role for local tumor control and the extent of neurosurgical resection has been the most consistent independent
prognostic factor reported in the last decades [5, 6, 34].
The favorable outcome of patients without residual disease
and the large difference in event-free and overall survival
between patients with complete versus incomplete resection (up to 50% in some series) have led to the concepts of
aggressive de-bulking and second-look surgery. Such neurosurgical procedures may be performed immediately following incomplete initial resection or after a short course
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of chemotherapy and is currently being systematically
evaluated in clinical trials. A comprehensive radiological
assessment of the residual disease status is expected to give
the highest degree of information to base potential secondary neurosurgical intervention decisions. Attendees agreed
that central radiological review of pre- and post-surgical
imaging should be a principal component of every clinical
trial enrolling patients with ependymoma henceforth.
In addition to surgery, post-operative field radiotherapy
dosed at 54–59.4 Gy is considered the standard of care for
patients with non-disseminated ependymoma to lower the
risk of local recurrence [25]. Radiation margins around the
target volume have also decreased from 2.0 to 1.0 cm, with
no evidence of increased frequency of tumor relapse [25].
Owing to the challenging localization of ependymoma,
particularly in the case of laterally located infant posterior
fossa tumors, proton therapy has been explored as a radiation modality to spare proximal neurological structures
[21]. In the case of recurrent ependymoma, a retrospective
analysis demonstrated that the efficacy of re-irradiation,
however, was associated with a decline in patient intellectual function [4].
It should be emphasized that all prior studies that evaluated the therapeutic value of neurosurgical interventions
and external beam radiation in posterior fossa ependymoma
have not accounted for molecular subgroup affiliation and
might therefore be confounded by clinical differences in
response to therapy between these subgroups. Data from a
current retrospective study on four independent non-overlapping cohorts of posterior fossa ependymomas (n = 820
cases) found that patients with either PF-EPN-A or PFEPN-B tumors benefit from gross total resection, with the
survival rates being particularly poor for sub-totally resected
PF-EPN-A, even in the setting of radiation therapy [31].
Participants at the conference concluded that for PF-EPNA tumors in patients older than 12 months of age who are
treated outside of clinical trials, maximal safe surgical
resection and focal radiotherapy should be defined as the
standard of care. Owing to the challenging localization of
PF-EPN-A tumors, attendees acknowledged that patients
would benefit from being treated in specialized centers by
experienced neurosurgeons. Since the study strongly demonstrates that a large subset of patients with PF-EPN-B
tumors who received a gross total resection did not recur,
even in the absence of radiotherapy, it was agreed that a randomized clinical trial for newly diagnosed and gross totally
resected PF-EPN-B ependymoma comparing observation
versus standard upfront radiation should be considered.
Such a trial would test the possibility of therapy to be deescalated in some patients with PF-EPN-B ependymoma.
Observation for gross totally resected supratentorial
ependymomas has also been advocated based on retrospective series that were not molecularly characterized. For
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example, a retrospective, multicenter study comprising 92
patients (median age was 17.5 years, range 1–83 years)
with gross totally resected and non-anaplastic supratentorial ependymal tumors did not find evidence of decreased
progression-free or overall survival with the omission of
external beam radiation [11]. The 5–10 year Kaplan–Meier
estimated overall survival for the overall cohort was 83.2
and 84.1%, respectively. Another retrospective review
of only ten patients (median age 5.6 years, range 1.8–
15.6 years), which also included ependymomas diagnosed
as WHO grade III, found that in some children with completely resected supratentorial ependymoma, surgery alone
may be an acceptable treatment option [35]. The outcomes
in the aforementioned series differed from the largest cohort
published to date comprising 122 supratentorial ependymal
tumors that were classified according to their DNA methylation profiles as ST-EPN-RELA, ST-EPN-YAP1 and ST-SE
[29]. Tumors harboring C11ORF95 gene fusions to RELA
accounted for more than 70% of supratentorial ependymomas (median age 8 years, range 0–69 years) and were associated with a poor prognosis with 5-year progression-free
and overall survival of 29 and 75%, respectively. Interestingly, the level of resection did not significantly affect
the outcome within the ST-EPN-RELA-positive subgroup
in this retrospective analysis in patient samples collected
over a long period of time (>20 years). The two remaining supratentorial subgroups, ST-SE and ST-EPN-YAP1,
were restricted only to adults (median age 40 years, range
22–76 years) and predominantly to children (median age
1.4 years, range 0–51 years), respectively, with both of
these variants showing an excellent prognosis. As the cited
studies and other available collections of single cases markedly differ regarding age distribution, therapy modalities
and availability of molecular data, variations in outcome
cannot be reliably linked to specific treatment approaches
or molecular subgroups. It was, therefore, concluded that
there was not enough evidence yet to recommend distinct
treatment approaches for ST-EPN-RELA ependymoma.
Molecular analyses of supratentorial ependymomas from
clinically well-annotated international trial cohorts as well
as from large retrospective cohorts with long-term followup have now been initiated. The authors expect that this
approach will help to clarify questions about the clinical
outcome of the molecular variants of supratentorial ependymoma and result in explicit therapy recommendations.
In contrast to surgery and radiotherapy, the role of
chemotherapy in the management of ependymoma remains
unproven despite extensive investigation. Cohorts of pediatric or adult patients in which the role of chemotherapy
was retrospectively analyzed either failed to demonstrate a survival advantage or showed substantial variation
between individual patients [3, 13, 28]. Two international
randomized trials in children are currently comparing
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post-irradiation chemotherapy to observation only, SIOP
Ependymoma II (Europe) and ACNS0831 (USA). In an
attempt to delay radiotherapy in very young children, driven
by concerns about long-term treatment toxicity, several
groups used post-operative chemotherapy approaches in
children under 3 years with 42% being the highest rate of
5-year progression-free survival reached to date [14, 15,
40]. In marked contrast, extension of immediate post-operative high-dose conformal radiotherapy to children under
the age of 3 years led to 7-year progression-free survival
rates of 77%, albeit long-term follow-up for toxic effects on
development are still pending [25]. For this reason, radiotherapy deferral strategies that use chemotherapy have been
abandoned in most institutions for children >12 months of
age. Initial responses to chemotherapy after subtotal resection have been demonstrated [10] and the ependymoma trial
ACNS0831 is currently assessing the role of neoadjuvant
chemotherapy and second-look surgery, with a combined
chemotherapy regimen of vincristine, cisplatin, etoposide,
and cyclophosphamide. To date, there is no chemotherapeutic regimen that can routinely be recommended outside the
context of a clinical trial. Since the consensus for therapeutic management in the molecularly well-defined PF-EPN-A
subgroup does not include any systemic therapy, it will definitely open new avenues for rather rapid implementation of
innovative trials for this devastating disease.

Model development and novel therapeutics
Because of the recognition that ependymal tumors comprise molecularly distinct subtypes, with potentially distinct
clinical management, the generation of subgroup-specific
pre-clinical models for the development and assessment of
novel therapies is required. The identification of candidate
cells of origin for ependymoma has permitted the generation of novel mouse models that can be leveraged for novel
therapeutic discovery and evaluation [1, 16, 27, 30]. Ephrin
receptor B2 (EPHB2)-driven ST ependymoma models—
also highly expressed in ST-EPN-RELA tumors—have
pinpointed 5-fluorouracil treatment as a potential cytotoxic
therapy with efficacy in murine models and is currently
being evaluated in early phase ependymoma clinical trials
[1, 16, 38]. Owing to the clear genetic drivers of ST-EPNRELA and ST-EPN-YAP1, transcriptionally faithful mouse
models are currently generated, which will create similar
opportunities to identify druggable targets against these
specific subtypes of ependymoma [30]. In parallel, patientderived xenograft (PDX) models have been established,
permitting further therapeutic evaluation of novel drugs and
compounds against ependymoma [2, 26, 39]. In the case of
PF-EPN-A, the absence of a clear genetic driver has hampered efforts to create genetic mouse models of the disease.
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Moving forward, it will be important that pre-clinical models are developed in the context of ependymoma subgroups,
such that molecular stratification of these tumors is paired
with specific therapeutic targets.

Conclusions
We now recognize that ependymal tumors from different
compartments of the central nervous system are biologically distinct and there are phenotypically divergent subgroups within each anatomic compartment. Future clinical
trials, the development of pre-clinical model systems, and
the identification and testing of subtype-specific therapeutics must accompany molecular classification to be useful
to ependymoma patients and to the neuro-oncology community. The differentiation between histologically defined
grade II versus grade III/anaplastic ependymomas is problematic and of limited utility for clinical decision-making,
and therefore should be used with great caution outside
the setting of a clinical trial. For patients with PF-EPN-A
ependymoma over the age of 12 months of age, the recommended standard of care is maximal safe micro-neurosurgical removal followed by local radiotherapy, but probably
does not include the routine use of chemotherapy outside
the setting of a clinical trial. A subset of PF-EPN-B ependymoma patients who undergo gross total micro-neurosurgical resection are likely cured in the absence of radiotherapy, and a clinical trial to test the possibility to avoid
radiotherapy in the context of complete resection for PFEPN-B patients is indicated. The characteristics and heterogeneity between molecular subgroups of supratentorial
ependymoma require additional study before specific treatment recommendations can be made. The division of an
already uncommon entity (“ependymoma”) into nine new
entities will necessitate great co-operation and international
collaboration with the pediatric and adult neuro-oncology
community if clinical trials are to be properly and expeditiously completed.
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